Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received an average rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $42.60.

COLL has been the topic of several recent analyst reports. HC Wainwright upped their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd.

Collegium Pharmaceutical Stock Down 2.8 %

Shares of COLL opened at $30.02 on Thursday. The company’s 50-day moving average price is $32.77 and its 200 day moving average price is $34.32. Collegium Pharmaceutical has a 12-month low of $28.97 and a 12-month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a market cap of $968.15 million, a P/E ratio of 12.94 and a beta of 0.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. Pacer Advisors Inc. boosted its stake in shares of Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after buying an additional 821,541 shares during the period. Rubric Capital Management LP grew its holdings in Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after acquiring an additional 499,473 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after acquiring an additional 215,874 shares in the last quarter. Emerald Advisers LLC increased its position in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after purchasing an additional 177,129 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its holdings in shares of Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock valued at $25,591,000 after purchasing an additional 131,835 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.